<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">HIV/AIDS continues to be one of the most challenging individual and public health concerns of our days .</segment>
<segment id="2" parent="1003" relname="attribution">According to the latest UNAIDS data ,</segment>
<segment id="3" parent="1003" relname="span">in 2018 , roughly 37.9 million individuals were infected with HIV globally ,</segment>
<segment id="4" parent="3" relname="circumstance">while around 770,000 people died of AIDS-related illness .</segment>
<segment id="5" parent="1005" relname="span">During that same year , an estimated 1.7 million new infections occurred ,</segment>
<segment id="6" parent="5" relname="elaboration">mainly due to unprotected sexual intercourse .</segment>
<segment id="7" parent="8" relname="concession">Investment in the field has been considerable ,</segment>
<segment id="8" parent="1007" relname="span">but a cure to the infection remains elusive .</segment>
<segment id="9" parent="1009" relname="span">Nonetheless , tremendous advances have been made over the last 36 years</segment>
<segment id="10" parent="11" relname="cause">since HIV-1 was identified ,</segment>
<segment id="11" parent="1010" relname="span">namely in prevention , diagnostics , and treatment .</segment>
<segment id="12" parent="1012" relname="span">The development of antiretroviral drugs and the introduction of highly active antiretroviral therapy</segment>
<segment id="13" parent="12" relname="elaboration">( HAART )</segment>
<segment id="14" parent="1014" relname="preparation">in the mid-1990s</segment>
<segment id="15" parent="1015" relname="preparation">—</segment>
<segment id="16" parent="1017" relname="span">currently referred to as combination antiretroviral therapy</segment>
<segment id="17" parent="16" relname="elaboration">( cART )</segment>
<segment id="18" parent="1016" relname="same_unit">—</segment>
<segment id="19" parent="1019" relname="preparation">led to a dramatic shift of AIDS from a fatal disease into a chronic and often stable medical condition .</segment>
<segment id="20" parent="1019" relname="joint">In fact , cART contributed decisively to a steady decrease in the number of HIV-related deaths since the first years of the new millennium .</segment>
<segment id="21" parent="1019" relname="joint">Antiretroviral drugs have also been found useful in the prevention field , particularly in post-exposure prophylaxis or mother-to-child transmission .</segment>
<segment id="22" parent="1023" relname="span">Treatment as prevention and pre-exposure prophylaxis</segment>
<segment id="23" parent="22" relname="elaboration">( PrEP )</segment>
<segment id="24" parent="1022" relname="same_unit">have further contributed to the reduction of sexually transmitted HIV infections .</segment>
<segment id="25" parent="1026" relname="span">Long-lasting injectable products and antiretroviral-based microbicides</segment>
<segment id="26" parent="25" relname="elaboration">that are currently in late stages of clinical development or regulatory approval</segment>
<segment id="27" parent="1025" relname="same_unit">may soon provide new options for prevention .</segment>
<segment id="28" parent="1019" relname="joint">Gene therapy and the use of broadly neutralizing antibodies are also attracting a great deal of interest as possible approaches to HIV/AIDS management .</segment>
<segment id="29" parent="1019" relname="joint">Still , different challenges remain in anti-HIV drug therapy/prophylaxis ,</segment>
<segment id="30" parent="1031" relname="span">and these include the following , among others :</segment>
<segment id="31" parent="30" relname="elaboration">( i )</segment>
<segment id="32" parent="1033" relname="span">the onset of severe adverse effects</segment>
<segment id="33" parent="1034" relname="span">leading to the discontinuation or interruption of therapy or even prophylaxis ;</segment>
<segment id="34" parent="33" relname="restatement">( ii )</segment>
<segment id="35" parent="1035" relname="span">sub-optimal biodistribution and pharmacokinetics , particularly in reservoir sites or mucosae</segment>
<segment id="36" parent="1037" relname="span">involved in sexual transmission ;</segment>
<segment id="37" parent="36" relname="restatement">( iii )</segment>
<segment id="38" parent="1039" relname="span">the occurrence of viral resistance ;</segment>
<segment id="39" parent="38" relname="restatement">( iv )</segment>
<segment id="40" parent="1041" relname="span">troublesome regimens and/or drug delivery routes</segment>
<segment id="41" parent="1042" relname="span">that lead to poor adherence by patients/users ;</segment>
<segment id="42" parent="41" relname="elaboration">( v )</segment>
<segment id="43" parent="1043" relname="span">low stability and reduced shelf-life of active molecules ,</segment>
<segment id="44" parent="1044" relname="span">which may be particularly challenging in tropical climates and low-resource regions</segment>
<segment id="45" parent="1046" relname="span">lacking adequate refrigerated distribution channels and storage ;</segment>
<segment id="46" parent="45" relname="restatement">( vi )</segment>
<segment id="47" parent="1048" relname="span">lack of suitable dosage forms for particular populations</segment>
<segment id="48" parent="1049" relname="span">( e. g. , children and women ) ;</segment>
<segment id="49" parent="48" relname="restatement">( vii )</segment>
<segment id="50" parent="1050" relname="span">costly drug products</segment>
<segment id="51" parent="1051" relname="joint">that are often inaccessible to populations in need of therapy/prophylaxis ;</segment>
<segment id="52" parent="1052" relname="same_unit">and ( viii )</segment>
<segment id="53" parent="1053" relname="span">social and legal constraints</segment>
<segment id="54" parent="53" relname="elaboration">resulting in poor access to and the discontinuation of anti-HIV therapy/prophylaxis .</segment>
<segment id="55" parent="1019" relname="joint">The response from the scientific community could not be more affirmative ,</segment>
<segment id="56" parent="1019" relname="joint">and novel ideas and concepts have been emerging throughout the last decade or so .</segment>
<segment id="57" parent="1057" relname="span">More important , innovative products are now under development ,</segment>
<segment id="58" parent="1058" relname="span">holding great promise</segment>
<segment id="59" parent="1059" relname="span">for mitigating many of the challenges</segment>
<segment id="60" parent="59" relname="elaboration">identified above .</segment>
<segment id="61" parent="1061" relname="span">This Special Issue presents an exciting series of reviews and original research articles from eminent scientists in academia and different nonprofit organizations</segment>
<segment id="62" parent="1062" relname="span">involved in the development of antiretroviral drug products ,</segment>
<segment id="63" parent="62" relname="elaboration">focusing mainly on novel strategies for the formulation and delivery of anti-HIV compounds .</segment>
<segment id="64" parent="1064" relname="span">Innovative approaches</segment>
<segment id="65" parent="64" relname="circumstance">towards improved gene therapy and immunotherapy are also addressed .</segment>
<segment id="66" parent="1019" relname="joint">The presented reports provide not only interesting overviews and opinion on recent developments in the broad field of antiretroviral therapy/prophylaxis and drug delivery ,</segment>
<segment id="67" parent="1067" relname="span">but also describe the development of new products</segment>
<segment id="68" parent="67" relname="elaboration">that are currently tracked for clinical testing .</segment>
<segment id="69" parent="1070" relname="span">The Special Issue starts with an interesting review by Tsukamoto at Kindai University , Japan , on strategies</segment>
<segment id="70" parent="69" relname="elaboration">explored</segment>
<segment id="71" parent="1071" relname="span">for curing HIV infection</segment>
<segment id="72" parent="71" relname="means">using a combination of gene therapy and host immunization .</segment>
<segment id="73" parent="1073" relname="span">In particular , the author emphasizes the possible role of anti-HIV intracellular immunization</segment>
<segment id="74" parent="73" relname="means">using gene silencing , among other approaches , in the protection of bone marrow hematopoietic stem/progenitor cells .</segment>
<segment id="75" parent="1074" relname="sequence">Still in the same field , Düzgüneş and Konopka at the University of the Pacific , USA , contributed a stimulating review on a potential strategy for the eradication of cellular reservoirs of HIV .</segment>
<segment id="76" parent="1076" relname="attribution">This thought-provoking piece explores</segment>
<segment id="77" parent="1076" relname="span">how such an objective could be achieved</segment>
<segment id="78" parent="1077" relname="span">by using suicide gene therapy</segment>
<segment id="79" parent="1078" relname="span">for killing HIV-infected cells , excision of chromosome-integrated viral DNA , and cytotoxic liposomes</segment>
<segment id="80" parent="79" relname="elaboration">targeted to latency-reversed HIV-infected cells .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="joint"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1005" type="span" parent="1001" relname="joint"/>
<group id="1007" type="span" parent="1001" relname="joint"/>
<group id="1008" type="span" parent="1001" relname="joint"/>
<group id="1009" type="span" parent="1011" relname="preparation"/>
<group id="1010" type="span" parent="9" relname="elaboration"/>
<group id="1011" type="span" parent="1008" relname="span"/>
<group id="1012" type="span" parent="1013" relname="preparation"/>
<group id="1013" type="span" parent="1011" relname="span"/>
<group id="1014" type="span" parent="1013" relname="span"/>
<group id="1015" type="span" parent="1014" relname="span"/>
<group id="1016" type="multinuc" parent="1018" relname="preparation"/>
<group id="1017" type="span" parent="1016" relname="same_unit"/>
<group id="1018" type="span" parent="1015" relname="span"/>
<group id="1019" type="multinuc" parent="1018" relname="span"/>
<group id="1022" type="multinuc" parent="1019" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="same_unit"/>
<group id="1025" type="multinuc" parent="1019" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="same_unit"/>
<group id="1030" type="multinuc" parent="1019" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="same_unit"/>
<group id="1032" type="multinuc" parent="1030" relname="same_unit"/>
<group id="1033" type="span" parent="1032" relname="same_unit"/>
<group id="1034" type="span" parent="32" relname="elaboration"/>
<group id="1035" type="span" parent="1032" relname="same_unit"/>
<group id="1036" type="multinuc" parent="35" relname="elaboration"/>
<group id="1037" type="span" parent="1036" relname="same_unit"/>
<group id="1038" type="multinuc" parent="1036" relname="same_unit"/>
<group id="1039" type="span" parent="1038" relname="same_unit"/>
<group id="1040" type="multinuc" parent="1038" relname="same_unit"/>
<group id="1041" type="span" parent="1040" relname="same_unit"/>
<group id="1042" type="span" parent="40" relname="elaboration"/>
<group id="1043" type="span" parent="1040" relname="same_unit"/>
<group id="1044" type="span" parent="43" relname="elaboration"/>
<group id="1045" type="multinuc" parent="44" relname="elaboration"/>
<group id="1046" type="span" parent="1045" relname="same_unit"/>
<group id="1047" type="multinuc" parent="1045" relname="same_unit"/>
<group id="1048" type="span" parent="1047" relname="same_unit"/>
<group id="1049" type="span" parent="47" relname="elaboration"/>
<group id="1050" type="span" parent="1047" relname="same_unit"/>
<group id="1051" type="multinuc" parent="50" relname="elaboration"/>
<group id="1052" type="multinuc" parent="1051" relname="joint"/>
<group id="1053" type="span" parent="1052" relname="same_unit"/>
<group id="1057" type="span" parent="1019" relname="joint"/>
<group id="1058" type="span" parent="57" relname="elaboration"/>
<group id="1059" type="span" parent="58" relname="purpose"/>
<group id="1061" type="span" parent="1019" relname="joint"/>
<group id="1062" type="span" parent="61" relname="elaboration"/>
<group id="1064" type="span" parent="1019" relname="joint"/>
<group id="1067" type="span" parent="1019" relname="joint"/>
<group id="1069" type="multinuc" parent="1019" relname="joint"/>
<group id="1070" type="span" parent="1069" relname="same_unit"/>
<group id="1071" type="span" parent="1069" relname="same_unit"/>
<group id="1073" type="span" parent="1019" relname="joint"/>
<group id="1074" type="multinuc" parent="1019" relname="joint"/>
<group id="1075" type="span" parent="1074" relname="sequence"/>
<group id="1076" type="span" parent="1075" relname="span"/>
<group id="1077" type="span" parent="77" relname="means"/>
<group id="1078" type="span" parent="78" relname="purpose"/>
	</body>
</rst>
